Overview of Labsalerg-B
| Property | Description |
|---|---|
| Active Ingredients | Betamethasone Dipropionate, Loratadine |
| Form | Fixed-dose combination (typically Oral Solid Form or Topical) |
| Pharmacological Class | Antihistamine-Corticosteroid Combination |
| Common Therapeutic Purpose | Systemic Anti-allergic and Anti-inflammatory Relief |
| Origin | Synthetic |
Labsalerg-B: Definition and Pharmacological Classification
Labsalerg-B is a pharmaceutical preparation defined as a fixed-dose combination drug product, which means it incorporates two distinct active pharmaceutical ingredients (APIs) within a single medicine. It is broadly categorized as a systemic anti-allergic and anti-inflammatory agent, belonging to the high-level class of antihistamine-corticosteroid combinations. This dual-ingredient structure is clinically recognized for its ability to address both acute allergy symptoms and underlying inflammatory components. The specific form may vary, such as an oral solid form for systemic use, which establishes its intended administrative route.
Active Components: Betamethasone Dipropionate and Loratadine
The composition of Labsalerg-B includes two principal synthetic components: Betamethasone Dipropionate and Loratadine. Betamethasone Dipropionate is a potent member of the synthetic glucocorticoid family, which serves as the corticosteroid ingredient. The inclusion of this potent component is a differentiating factor from standard over-the-counter allergy medications that typically rely only on a single antihistamine. Loratadine is a widely used second-generation, tricyclic H1-antihistamine. Loratadine is known for relieving allergic symptoms without the marked sedative effects often associated with older classes.
General Purpose of the Dual-Action Medicine
The general purpose of Labsalerg-B is to manage conditions where both inflammation and allergic activity are concurrent problems, such as persistent allergic discomfort requiring more than single-agent relief. The medicine delivers a dual-action pharmacology: the corticosteroid component provides anti-inflammatory relief by suppressing the underlying chronic tissue response, and the antihistamine component offers anti-pruritic (anti-itch) and anti-allergic relief by blocking histamine receptors. This combination strategy is designed to provide a robust and comprehensive approach to managing both the immediate allergic symptoms and the associated inflammatory state.
Regulatory References
